Teladoc (TDOC) Stock Drops Despite Market Gains: Important Facts to Note

11.09.25 00:15 Uhr

Werte in diesem Artikel
Aktien

1.285,00 JPY -6,00 JPY -0,46%

6,79 EUR -0,30 EUR -4,26%

In the latest close session, Teladoc (TDOC) was down 3.97% at $7.49. The stock's performance was behind the S&P 500's daily gain of 0.3%. At the same time, the Dow lost 0.48%, and the tech-heavy Nasdaq gained 0.03%. Shares of the telehealth services provider have appreciated by 13.54% over the course of the past month, outperforming the Medical sector's gain of 7.07%, and the S&P 500's gain of 2.09%.The upcoming earnings release of Teladoc will be of great interest to investors. The company's earnings per share (EPS) are projected to be -$0.24, reflecting a 26.32% decrease from the same quarter last year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $625.56 million, down 2.33% from the year-ago period. For the full year, the Zacks Consensus Estimates project earnings of -$1.17 per share and a revenue of $2.52 billion, demonstrating changes of +80.07% and -1.82%, respectively, from the preceding year. Investors might also notice recent changes to analyst estimates for Teladoc. Such recent modifications usually signify the changing landscape of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook. Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system. The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.36% lower. Teladoc is currently a Zacks Rank #3 (Hold). The Medical Services industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 146, positioning it in the bottom 41% of all 250+ industries. The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. To follow TDOC in the coming trading sessions, be sure to utilize Zacks.com. Free Report: Profiting from the 2nd Wave of AI ExplosionThe next phase of the AI explosion is poised to create significant wealth for investors, especially those who get in early. It will add literally trillion of dollars to the economy and revolutionize nearly every part of our lives.Investors who bought shares like Nvidia at the right time have had a shot at huge gains.But the rocket ride in the "first wave" of AI stocks may soon come to an end. The sharp upward trajectory of these stocks will begin to level off, leaving exponential growth to a new wave of cutting-edge companies.Zacks' AI Boom 2.0: The Second Wave report reveals 4 under-the-radar companies that may soon be shining stars of AI’s next leap forward.Access AI Boom 2.0 now, absolutely free >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Teladoc Health, Inc. (TDOC): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

In eigener Sache

Übrigens: Teladoc und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und Neukunden-Bonus sichern!

Ausgewählte Hebelprodukte auf note

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf note

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu Teladoc Inc

Wer­bung

Analysen zu Teladoc Inc

DatumRatingAnalyst
02.11.2018Teladoc BuyChardan Capital Markets
03.08.2018Teladoc BuyChardan Capital Markets
05.06.2018Teladoc BuyCanaccord Adams
15.03.2018Teladoc HoldDeutsche Bank AG
28.02.2018Teladoc BuyChardan Capital Markets
DatumRatingAnalyst
02.11.2018Teladoc BuyChardan Capital Markets
03.08.2018Teladoc BuyChardan Capital Markets
05.06.2018Teladoc BuyCanaccord Adams
28.02.2018Teladoc BuyChardan Capital Markets
08.12.2017Teladoc BuyDeutsche Bank AG
DatumRatingAnalyst
15.03.2018Teladoc HoldDeutsche Bank AG
18.09.2017Teladoc NeutralRobert W. Baird & Co. Incorporated
DatumRatingAnalyst

Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar.

Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Teladoc Inc nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen